These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 8742969

  • 1. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome.
    Segarra A, Chacón P, Piera LL.
    Nephron; 1996; 73(1):102-3. PubMed ID: 8742969
    [No Abstract] [Full Text] [Related]

  • 2. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome.
    Hong SY, Yang DH.
    Nephron; 1995; 69(2):125-30. PubMed ID: 7723892
    [Abstract] [Full Text] [Related]

  • 3. Lipoprotein(a) levels in the nephrotic syndrome.
    Craig WY, Ritchie RF.
    Ann Intern Med; 1994 Jan 15; 120(2):165-6. PubMed ID: 8110266
    [No Abstract] [Full Text] [Related]

  • 4. Unusually high concentrations of serum lipoprotein(a) in a child with nephrotic syndrome.
    Garnotel R, Roussel B, Monier F, Gillery P.
    Clin Nephrol; 1998 Nov 15; 50(5):334-5. PubMed ID: 9840325
    [No Abstract] [Full Text] [Related]

  • 5. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
    Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH.
    J Lab Clin Med; 1994 Jul 15; 124(1):118-24. PubMed ID: 7518491
    [Abstract] [Full Text] [Related]

  • 6. Serum remnant lipoprotein levels in nephrotic syndrome.
    Kinoshita H, Uezono S, Fukudome K, Yokota N, Hisanaga S, Fujimoto S, Eto T.
    Clin Nephrol; 2001 Mar 15; 55(3):263-4. PubMed ID: 11316252
    [No Abstract] [Full Text] [Related]

  • 7. Lipoprotein(a) in patients with the nephrotic syndrome: influence of immunosuppression and proteinuria.
    Wanner C, Bartens W, Nauck M, Zäuner I, Greiber S, Schollmeyer P.
    Miner Electrolyte Metab; 1996 Mar 15; 22(1-3):26-30. PubMed ID: 8676820
    [Abstract] [Full Text] [Related]

  • 8. Plasma lipoprotein (a) levels in children with minimal lesion nephrotic syndrome.
    Nakahara C, Kobayashi K, Hamaguchi H, Kanemoto K, Kashiwagi R, Matsui A.
    Pediatr Nephrol; 1999 Oct 15; 13(8):657-61. PubMed ID: 10502122
    [Abstract] [Full Text] [Related]

  • 9. [Fibrinolytic and lipid disturbances in patients with nephrotic syndrome].
    Małyszko J, Małyszko JS, Mysliwiec M.
    Pol Arch Med Wewn; 1994 Nov 15; 92(5):394-9. PubMed ID: 7885987
    [Abstract] [Full Text] [Related]

  • 10. Behaviour of fibrinolysis in the nephrotic syndrome.
    Cucuianu M, Manasia M, Spînu C, Mărcuşu C, Roman S, Comănescu A.
    Med Interne; 1988 Nov 15; 26(2):109-14. PubMed ID: 3133746
    [Abstract] [Full Text] [Related]

  • 11. [Evaluation of selected parameters of hemostasis in patients with nephrotic syndrome].
    Rowiński M, Rydzewski A, Małyszko JS, Małyszko J, Myśliwiec M.
    Przegl Lek; 1994 Nov 15; 51(2):77-81. PubMed ID: 8058973
    [Abstract] [Full Text] [Related]

  • 12. [Functional status of the hemostatic and fibrinolytic systems in patients with clinical variants of chronic glomerulonephritis].
    Miagkov II, Nazar PS.
    Ter Arkh; 1989 Nov 15; 61(11):123-6. PubMed ID: 2633374
    [Abstract] [Full Text] [Related]

  • 13. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
    Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, König P, Thiery J, Koch M, von Eckardstein A, Dieplinger H.
    Kidney Int; 2004 Jul 15; 66(1):348-54. PubMed ID: 15200443
    [Abstract] [Full Text] [Related]

  • 14. [Prognostic significance of the state of the fibrinolytic system and evaluation of its functional possibilities in nephrotic syndrome].
    Poliantseva LR, Podorol'skaia LV, Nevraeva OG, Andreenko GV.
    Ter Arkh; 1978 Jul 15; 50(11):84-91. PubMed ID: 725768
    [No Abstract] [Full Text] [Related]

  • 15. [Effect of diet of various protein contents on the blood fibrinolytic system in the nephrotic syndrome].
    Samsonov MA, Andreenko GV, Poliantseva LR, Agadzhanov SA, Nevraeva OG.
    Ter Arkh; 1980 Jul 15; 52(12):79-82. PubMed ID: 7245076
    [No Abstract] [Full Text] [Related]

  • 16. Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome.
    Noto D, Barbagallo CM, Cascio AL, Cefalù AB, Cavera G, Caldarella R, Marino G, Travali S, Cutaia I, Maringhini S, Notarbartolo A, Averna M.
    Kidney Int; 1999 Jun 15; 55(6):2433-9. PubMed ID: 10354292
    [Abstract] [Full Text] [Related]

  • 17. [Fibrinolytic system in patients with nephrotic syndrome].
    Andreenko GV, Poliantseva LR, Smirnova TA, Podorol'skaia LV.
    Ter Arkh; 1976 Jun 15; 40(2):89-99. PubMed ID: 135367
    [No Abstract] [Full Text] [Related]

  • 18. Thromboelastographic analysis of coagulation and fibrinolysis in rats with nephrotic syndrome induced by daunomycin.
    Shimizu K.
    Nihon Jinzo Gakkai Shi; 1991 May 15; 33(5):491-6. PubMed ID: 1895548
    [Abstract] [Full Text] [Related]

  • 19. Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome.
    Wanner C, Böhler J, Eckardt HG, Wieland H, Schollmeyer P.
    Clin Nephrol; 1994 Mar 15; 41(3):138-43. PubMed ID: 8187355
    [Abstract] [Full Text] [Related]

  • 20. [Abnormal coagulation and fibrinolytic activities in glomerulonephritis and nephrotic syndrome].
    Nakagawa M, Nishio A.
    Nihon Rinsho; 1984 Jun 15; 42(6):1386-92. PubMed ID: 6482002
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.